Name: 글로벌 시장 동향
SKU: PH3478
Availability: InStock

보고서 요약(국문)

보고서 개요
전 세계 비침습적 당뇨병 치료 시장은 2023년 2억 4,530만 달러에 달했으며, 2024년부터 2031년까지 연평균 7.9%의 성장률을 기록하며 2031년에는 4억 4,610만 달러에 이를 것으로 예상됩니다.
당뇨병은 췌장에서 인슐린이 충분히 생산되지 않거나 신체가 생산된 인슐린을 효과적으로 사용하지 못할 때 발생하는 만성 질환입니다. 인슐린은 혈당을 조절하는 호르몬입니다. 고혈당증(혈당 수치 상승)은 조절되지 않은 당뇨병의 흔한 증상이며, 시간이 지남에 따라 신체의 여러 기관, 특히 신경과 혈관에 심각한 손상을 초래합니다.
제1형 당뇨병(인슐린 의존성, 소아형 또는 아동기 발병형이라고도 함)은 인슐린 생산 부족이 특징이며 매일 인슐린 투여가 필요합니다. 제2형 당뇨병은 신체가 에너지를 위해 당을 사용하는 방식에 영향을 미칩니다. 신체가 인슐린을 제대로 사용하지 못하게 하여 치료하지 않으면 혈당 수치가 높아질 수 있습니다. 시간이 지남에 따라 제2형 당뇨병은 신체, 특히 신경과 혈관에 심각한 손상을 초래할 수 있습니다. 제2형 당뇨병은 예방 가능한 경우가 많습니다. 제2형 당뇨병 발병에 영향을 미치는 요인으로는 과체중, 운동 부족, 유전적 요인 등이 있습니다.
비침습적 의료 시술이란 피부에 절개선이 생기지 않고 점막, 피부 손상 부위 또는 신체 내부 장기(자연적 또는 인공적 개구부를 제외한)와 접촉하지 않는 시술을 말합니다. 비침습적 치료는 당뇨병 치료에서 가장 중요한 방법 중 하나입니다.
시장 동향: 성장 동력
당뇨병 유병률 증가
당뇨병 유병률 증가는 시장 성장을 견인하는 요인입니다. 예를 들어, 세계보건기구(WHO)에 따르면 전 세계적으로 약 4억 2,200만 명이 당뇨병을 앓고 있으며, 이들 대부분은 저소득 및 중소득 국가에 거주하고 있습니다. 또한 매년 150만 명이 당뇨병으로 사망합니다. 당뇨병 발병 건수와 유병률은 지난 수십 년 동안 꾸준히 증가해 왔습니다.

또한, 2023년 6월 건강계량평가연구소(IHME)에서 발표한 기사에 따르면, 가장 최근이자 가장 포괄적인 계산 결과 현재 전 세계 당뇨병 유병률은 6.1%로, 당뇨병은 사망 및 장애를 유발하는 10대 질병 중 하나입니다. 지역별로는 북아프리카 및 중동 지역의 유병률이 9.3%로 가장 높으며, 2050년에는 16.8%까지 증가할 것으로 예상됩니다. 라틴 아메리카 및 카리브해 지역의 유병률은 11.3%로 증가할 것으로 전망됩니다.
특히 모든 국가에서 65세 이상 노인층에서 당뇨병이 두드러지게 나타났으며, 전 세계적으로 이 연령대의 유병률은 20%를 넘었습니다. 가장 높은 비율은 75세에서 79세 사이 연령대에서 24.4%였습니다. 지역별로 살펴보면, 북아프리카 및 중동 지역이 이 연령대에서 39.4%로 가장 높은 비율을 보였고, 중앙 유럽, 동유럽 및 중앙아시아 지역은 19.8%로 가장 낮은 비율을 기록했습니다.
제약 요인
제품의 높은 가격과 모니터링 정확도의 한계는 시장 성장을 저해할 것으로 예상됩니다. 당뇨병 치료에 사용되는 제품의 가격이 높을 뿐만 아니라, 당뇨병은 만성 질환이므로 장기간 약물 치료가 필요하기 때문에 경제적 부담이 가중됩니다.
시장 세분화 분석
전 세계 비침습적 당뇨병 치료 시장은 제품, 당뇨병 유형, 최종 사용자 및 지역별로 세분화됩니다.
경구용 인슐린 부문은 전 세계 비침습적 당뇨병 치료 시장에서 약 56.4%의 점유율을 차지했습니다.
경구용 인슐린 부문은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 이 분야에서는 기술 발전과 임상 시험을 위한 민간 제조업체의 자금 증가가 시장 성장을 견인할 것입니다.
경구용 인슐린은 위장관에서 문맥으로 흡수되는 생리적 경로를 그대로 모방하여 간에 직접 작용하고 포도당 대사에서의 간 기능을 회복시킴으로써 유익한 대사적 효과를 가져올 수 있습니다. 또한, 경구용 인슐린은 고인슐린혈증 감소, 전신 인슐린 요법과 관련된 체중 증가 예방, 저혈당 위험 감소 등 임상적으로 유익한 추가적인 이점을 제공할 가능성이 높습니다.
예를 들어, 2024년 6월, 리 연구소(Li Lab)의 샤이다르 리(Shyh-Dar Li) 박사 연구팀은 혀 밑에 놓으면 체내에 빠르고 효율적으로 흡수되는 경구용 인슐린 방울을 개발하여 인슐린 주사의 필요성을 대체할 가능성을 열었습니다. 이 방울에는 인슐린과 특수한 세포 투과 펩타이드(CPP)가 혼합되어 있습니다.

시장 지역 분석
북미는 전 세계 비침습적 당뇨병 치료 시장 점유율의 약 42.1%를 차지했습니다.
북미 지역은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 이 지역의 당뇨병 발병률 증가와 기술 발전이 시장 성장을 견인하고 있습니다.
예를 들어, 미국 질병통제예방센터(CDC)에 따르면 2023년 11월 기준 미국에서 당뇨병 또는 당뇨병 전단계인 성인은 약 1억 3,600만 명으로 추산됩니다. 남녀 모두에서 당뇨병 진단 유병률은 미국 원주민 및 알래스카 원주민 성인(13.6%)에서 가장 높았고, 그 다음으로 비히스패닉 흑인 성인(12.1%), 히스패닉계 성인(11.7%), 비히스패닉 아시아계 성인(9.1%), 비히스패닉 백인 성인(6.9%) 순이었습니다. 연방 빈곤선 기준 500% 이상의 가구 소득을 가진 성인의 경우, 남성(6.3%)과 여성(3.9%) 모두에서 당뇨병 유병률이 가장 낮았으며, 이는 빈곤선 이하의 가구 소득을 가진 성인의 경우(13.1%)와 비교됩니다.
또한, 2023년 6월 FDA는 10세 이상 제2형 당뇨병 소아 환자의 혈당 조절 개선을 위해 식이요법 및 운동과 병행하여 사용하는 엠파글리플로진(자디앙스)과 엠파글리플로진/메트포르민 염산염(신자디)을 승인했습니다.

시장 세분화
제품별
경구용 인슐린
ORMD-0801
엘리젠
IN-105
마크룰린
구강 인슐린
오랄린
기타
안구용 인슐린
흡입용 인슐린
엑수베라
아프레자
테크노스피어 인슐린
AERx iDMS
에어로도스
비강 인슐린
나슐린
Q도스
기타
경피 인슐린
기타
당뇨병 유형별
1형
2형
최종 사용자별
병원
전문 클리닉
가정 간호
기타
지역별
북미
미국
캐나다
멕시코
유럽
독일
영국
프랑스
스페인
이탈리아
기타 유럽 지역
남미
브라질
아르헨티나
기타 남미 지역 미국
아시아 태평양
중국
인도
일본
한국
기타 아시아 태평양 지역
중동 및 아프리카
시장 경쟁 환경
전 세계 비침습적 당뇨병 치료제 시장의 주요 기업으로는 오라메드(Oramed), 노보 노디스크(Novo Nordisk A/S), 바이오콘(Biocon), 머크(Merck KGaA), 화이자(Pfizer Inc.), 테바(Teva Pharmaceutical Industries Ltd.), 애보트(Abbott), 아스트라제네카(AstraZeneca), 일라이 릴리(Eli Lilly and Company), 노바티스(Novartis AG) 등이 있습니다.
주요 개발 사항
2024년 1월, 제약 회사 루핀(Lupin)은 미국 식품의약국(FDA)으로부터 당뇨병 치료용 제네릭 의약품 판매 승인을 받았다고 발표했습니다. 루핀은 다파글리플로진(Dapagliflozin)과 삭사글립틴(Saxagliptin) 정제에 대한 약식 신약 신청(ANDA) 승인을 받았습니다.
2024년 7월, 자이더스 라이프사이언스(Zydus Lifesciences)는 당뇨병 치료제 신약 신청에 대해 미국 FDA의 승인을 받았습니다. 해당 회사는 미국 식품의약국(USFDA)으로부터 지투비멧 XR(시타글립틴 및 메트포르민 염산염)의 시판을 위한 신약 허가 신청(NDA) 최종 승인을 받았습니다.
보고서 구매 이유:
제품, 당뇨병 유형, 최종 사용자 및 지역별 글로벌 비침습적 당뇨병 치료 시장 세분화를 시각화하고 주요 상업 자산 및 플레이어를 파악하기 위함입니다.
트렌드 분석 및 공동 개발을 통해 사업 기회를 식별할 수 있습니다.
모든 세그먼트를 포함한 글로벌 비침습적 당뇨병 치료 시장 수준의 다양한 데이터 포인트가 담긴 Excel 데이터 시트를 제공합니다.
PDF 보고서는 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석 자료입니다.
모든 주요 플레이어의 핵심 제품을 포함하는 제품 매핑 Excel 파일을 제공합니다.
글로벌 비침습적 당뇨병 치료 시장 보고서는 약 51개의 표, 54개의 그림, 181페이지로 구성됩니다.
대상 고객(2024년):
제조업체/구매자
산업 투자자/투자 은행가
연구 전문가
신흥 기업

보고서 요약(영어 원문)

Report Overview
The Global Non-Invasive Diabetes Therapy Market reached US$ 245.3 million in 2023 and is expected to reach US$ 446.1 million by 2031, growing at a CAGR of 7.9% during the forecast period 2024-2031.
Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Insulin is a hormone that regulates blood glucose. Hyperglycaemia, also called raised blood glucose or raised blood sugar, is a common effect of uncontrolled diabetes and over time leads to serious damage to many of the body's systems, especially the nerves and blood vessels.
Type 1 diabetes, also known as insulin-dependent, juvenile, or childhood-onset is characterized by deficient insulin production and requires daily administration of insulin. Type 2 diabetes affects how the body uses sugar for energy. It stops the body from using insulin properly, which can lead to high levels of blood sugar if not treated. Over time, type 2 diabetes can cause serious damage to the body, especially nerves and blood vessels. Type 2 diabetes is often preventable. Factors that contribute to developing type 2 diabetes include being overweight, not getting enough exercise, and genetics.
A medical procedure is defined as non-invasive when no break in the skin is created and there is no contact with the mucosa, skin break, or internal body cavity beyond a natural or artificial body orifice. The non-invasive treatment is one of the most important methods involved in diabetes therapeutics.
Market Dynamics: Drivers
Increasing prevalence of diabetes
The rising prevalence of diabetes propels the market growth. For instance, according to the World Health Organization, about 422 million people worldwide have diabetes, the majority living in low-and middle-income countries, and 1.5 million deaths are directly attributed to diabetes each year. Both the number of cases and the prevalence of diabetes have been steadily increasing over the past few decades.
Moreover, according to an article published by the Institute for Health Metrics and Evaluation in June 2023, The latest and most comprehensive calculations show the current global prevalence rate is 6.1%, making diabetes one of the top 10 leading causes of death and disability. At the super-region level, the highest rate is 9.3% in North Africa and the Middle East, and that number is projected to jump to 16.8% by 2050. The rate in Latin America and the Caribbean is projected to increase to 11.3%.
Diabetes was especially evident in people 65 and older in every country and recorded a prevalence rate of more than 20% for that demographic worldwide. The highest rate was 24.4% for those between ages 75 and 79. Examining the data by super-region, North Africa and the Middle East had the highest rate at 39.4% in this age group, while Central Europe, Eastern Europe, and Central Asia had the lowest rate at 19.8%.
Restraints
Factors such as high cost associated with the products, and accuracy of monitoring are expected to hamper the market. The prices of the products that are used for diabetes are high. Since diabetes is a chronic disease, the medication must be followed for a very long time which results in a decrease in the affordability rate.
Market Segment Analysis
The global non-invasive diabetes therapy market is segmented based on product, diabetes type, end-user, and region.
The segment oral insulin accounted for approximately 56.4% of the global non-invasive diabetes therapy market share
The oral insulin segment is expected to hold the largest market share over the forecast period. In this segment, technological advancements, and rising funds for private manufacturers for clinical trials would drive this market.
Oral insulin mimics this precise physiologic route as it is absorbed from the gastrointestinal tract into the portal vein and consequently may have salutary metabolic consequences due to the direct engagement of the liver and the resumption of its role in glucose metabolism. Furthermore, oral insulin is likely to convey additional advantages with plausible beneficial clinical ramifications, including the reduction of hyperinsulinemia, the forestalling of weight gain associated with systemic insulin therapy, and reducing the risk of hypoglycemia.
For instance, in June 2024, Dr. Shyh-Dar Li and his research team at the Li Lab developed oral insulin drops that when placed under the tongue are quickly and efficiently absorbed by the body, potentially replacing the need for insulin injections. The drops contain a mixture of insulin and a unique cell-penetrating peptide (CPP).
Market Geographical Analysis
North America accounted for approximately 42.1% of the global non-invasive diabetes therapy market share
North America region is expected to hold the largest market share over the forecast period. The rising incidence of diabetes, and technological advancements, in this region, help to propel the market.
For instance, according to the Centers for Disease Control and Prevention (CDC), in November 2023, it is estimated that, estimates that 136 million adults are living with diabetes or prediabetes in the United States. For both men and women, the prevalence of diagnosed diabetes was highest among American Indian and Alaskan Native adults (13.6%), followed by non-Hispanic Black adults (12.1%), adults of Hispanic origin (11.7%), non-Hispanic Asian adults (9.1%), and non-Hispanic White adults (6.9%). Adults with a family income above 500% of the federal poverty level had the lowest prevalence of diabetes for both men (6.3%) and women (3.9%), compared to families with a family income at or below the poverty level (13.1%).
Moreover in June 2023, The FDA approved empagliflozin (Jardiance) and empagliflozin/metformin hydrochloride (Synjardy) used with diet and exercise to improve blood sugar control in children 10 years and older with type 2 diabetes.
Market Segmentation
By Product
Oral Insulin
ORMD-0801
Eligen
IN-105
Macrulin
Buccal Insulin
Oral-Lyn
Others
Ocular Insulin
Inhaled Insulin
Exubera
Afrezza
Technosphere insulin
AERx iDMS
Aerodose
Nasal Insulin
Nasulin
QDose
Others
Transdermal Insulin
Others
By Diabetes Type
Type 1
Type 2
By End-User
Hospitals
Specialty Clinics
Homecare
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the global non-invasive diabetes therapy market include Oramed, Novo Nordisk A/S, Biocon, Merck KGaA, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Abbott, AstraZeneca, Eli Lilly and Company, Novartis AG among others.
Key Developments
In January 2024, Drug firm Lupin announced that it had received approval from the US health regulator to market a generic medication to treat diabetes. The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application for Dapagliflozin and Saxagliptin tablets.
In July 2024, Zydus Lifesciences received approval from the US health regulator for its new drug application for diabetes medication. The company has received final approval for its new drug application (NDA) from the US Food and Drug Administration (USFDA) to market Zituvimet XR (sitagliptin and metformin hydrochloride).
Why Purchase the Report?
To visualize the global non-invasive diabetes therapy market segmentation based on product, diabetes type, end-user, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of global non-invasive diabetes therapy market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.
The global non-invasive diabetes therapy market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product
3.2. Snippet by Diabetes Type
3.3. Snippet by End-User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Diabetes
4.1.2. Restraints
4.1.2.1. High Cost Associated with the Products
4.1.2.2. Accuracy of Monitoring
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Product
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
6.1.2. Market Attractiveness Index, By Product
6.2. Oral Insulin*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Buccal Insulin
6.4. Ocular Insulin
6.5. Inhaled Insulin
6.6. Nasal Insulin
6.7. Transdermal Insulin
6.8. Others
7. By Diabetes Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diabetes Type
7.1.2. Market Attractiveness Index, By Diabetes Type
7.2. Type 1*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Type 2
8. By End-User
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Specialty Clinics
8.4. Homecare
8.5. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diabetes Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diabetes Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. UK
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diabetes Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diabetes Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diabetes Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Oramed *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Novo Nordisk A/S
11.3. Biocon
11.4. Merck KGaA
11.5. Pfizer Inc.
11.6. Teva Pharmaceutical Industries Ltd.
11.7. Abbott
11.8. AstraZeneca
11.9. Eli Lilly and Company
11.10. Novartis AG (*LIST NOT EXHAUSTIVE)
12. Appendix
12.1. About Us and Services
12.2. Contact Us

언급된 주요 기업들

Oramed, 4.	Key Developments, Novo Nordisk A/S, Biocon, Merck KGaA, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Abbott, AstraZeneca, Eli Lilly and Company

표 목록 (Tables)

List of Tables

Table 1 Global Non-Invasive Diabetes Therapy Market Value, By Product, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Non-Invasive Diabetes Therapy Market Value, By Diabetes Type, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Non-Invasive Diabetes Therapy Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Non-Invasive Diabetes Therapy Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Non-Invasive Diabetes Therapy Market Value, By Product, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Non-Invasive Diabetes Therapy Market Value, By Product, 2022-2031 (US$ Million)

Table 7 Global Non-Invasive Diabetes Therapy Market Value, By Diabetes Type, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Non-Invasive Diabetes Therapy Market Value, By Diabetes Type, 2022-2031 (US$ Million)

Table 9 Global Non-Invasive Diabetes Therapy Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Non-Invasive Diabetes Therapy Market Value, By End-User, 2022-2031 (US$ Million)

Table 11 Global Non-Invasive Diabetes Therapy Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Non-Invasive Diabetes Therapy Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Non-Invasive Diabetes Therapy Market Value, By Product, 2022-2031 (US$ Million)

Table 14 North America Non-Invasive Diabetes Therapy Market Value, By Diabetes Type, 2022-2031 (US$ Million)

Table 15 North America Non-Invasive Diabetes Therapy Market Value, By End-User, 2022-2031 (US$ Million)

Table 16 North America Non-Invasive Diabetes Therapy Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Non-Invasive Diabetes Therapy Market Value, By Product, 2022-2031 (US$ Million)

Table 18 South America Non-Invasive Diabetes Therapy Market Value, By Diabetes Type, 2022-2031 (US$ Million)

Table 19 South America Non-Invasive Diabetes Therapy Market Value, By End-User, 2022-2031 (US$ Million)

Table 20 South America Non-Invasive Diabetes Therapy Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Non-Invasive Diabetes Therapy Market Value, By Product, 2022-2031 (US$ Million)

Table 22 Europe Non-Invasive Diabetes Therapy Market Value, By Diabetes Type, 2022-2031 (US$ Million)

Table 23 Europe Non-Invasive Diabetes Therapy Market Value, By End-User, 2022-2031 (US$ Million)

Table 24 Europe Non-Invasive Diabetes Therapy Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Non-Invasive Diabetes Therapy Market Value, By Product, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Non-Invasive Diabetes Therapy Market Value, By Diabetes Type, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Non-Invasive Diabetes Therapy Market Value, By End-User, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Non-Invasive Diabetes Therapy Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East and Africa Non-Invasive Diabetes Therapy Market Value, By Product, 2022-2031 (US$ Million)

Table 30 Middle East and Africa Non-Invasive Diabetes Therapy Market Value, By Diabetes Type, 2022-2031 (US$ Million)

Table 31 Middle East and Africa Non-Invasive Diabetes Therapy Market Value, By End-User, 2022-2031 (US$ Million)

Table 32 Middle East and Africa Non-Invasive Diabetes Therapy Market Value, By Country, 2022-2031 (US$ Million)

Table 33 Oramed: Overview

Table 34 Oramed: Product Portfolio

Table 35 Oramed: Key Developments

Table 36 Novo Nordisk A/S: Overview

Table 37 Novo Nordisk A/S: Product Portfolio

Table 38 Novo Nordisk A/S: Key Developments

Table 39 Biocon: Overview

Table 40 Biocon: Product Portfolio

Table 41 Biocon: Key Developments

Table 42 Merck KGaA: Overview

Table 43 Merck KGaA: Product Portfolio

Table 44 Merck KGaA: Key Developments

Table 45 Pfizer Inc.: Overview

Table 46 Pfizer Inc.: Product Portfolio

Table 47 Pfizer Inc.: Key Developments

Table 48 Teva Pharmaceutical Industries Ltd.: Overview

Table 49 Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 50 Teva Pharmaceutical Industries Ltd.: Key Developments

Table 51 Abbott: Overview

Table 52 Abbott: Product Portfolio

Table 53 Abbott: Key Developments

Table 54 AstraZeneca: Overview

Table 55 AstraZeneca: Product Portfolio

Table 56 AstraZeneca: Key Developments

Table 57 Eli Lilly and Company: Overview

Table 58 Eli Lilly and Company: Product Portfolio

Table 59 Eli Lilly and Company: Key Developments

Table 60 Novartis AG: Overview

Table 61 Novartis AG: Product Portfolio

Table 62 Novartis AG: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Non-Invasive Diabetes Therapy Market Value, 2022-2031 (US$ Million)

Figure 2 Global Non-Invasive Diabetes Therapy Market Share, By Product, 2023 & 2031 (%)

Figure 3 Global Non-Invasive Diabetes Therapy Market Share, By Diabetes Type, 2023 & 2031 (%)

Figure 4 Global Non-Invasive Diabetes Therapy Market Share, By End-User, 2023 & 2031 (%)

Figure 5 Global Non-Invasive Diabetes Therapy Market Share, By Region, 2023 & 2031 (%)

Figure 6 Global Non-Invasive Diabetes Therapy Market Y-o-Y Growth, By Product, 2023-2031 (%)

Figure 7 Oral Insulin Non-Invasive Diabetes Therapy Market Value, 2022-2031 (US$ Million)

Figure 8 Buccal Insulin Non-Invasive Diabetes Therapy Market Value, 2022-2031 (US$ Million)

Figure 9 Ocular Insulin Non-Invasive Diabetes Therapy Market Value, 2022-2031 (US$ Million)

Figure 10 Inhaled Insulin Non-Invasive Diabetes Therapy Market Value, 2022-2031 (US$ Million)

Figure 11 Nasal Insulin Non-Invasive Diabetes Therapy Market Value, 2022-2031 (US$ Million)

Figure 12 Transdermal Insulin Non-Invasive Diabetes Therapy Market Value, 2022-2031 (US$ Million)

Figure 13 Others Non-Invasive Diabetes Therapy Market Value, 2022-2031 (US$ Million)

Figure 14 Global Non-Invasive Diabetes Therapy Market Y-o-Y Growth, By Diabetes Type, 2023-2031 (%)

Figure 15 Type 1 Diabetes Type in Global Non-Invasive Diabetes Therapy Market Value, 2022-2031 (US$ Million)

Figure 16 Type 2 Diabetes Type in Global Non-Invasive Diabetes Therapy Market Value, 2022-2031 (US$ Million)

Figure 17 Global Non-Invasive Diabetes Therapy Market Y-o-Y Growth, By End-User, 2023-2031 (%)

Figure 18 Hospitals End-User in Global Non-Invasive Diabetes Therapy Market Value, 2022-2031 (US$ Million)

Figure 19 Specialty Clinics End-User in Global Non-Invasive Diabetes Therapy Market Value, 2022-2031 (US$ Million)

Figure 20 Homecare End-User in Global Non-Invasive Diabetes Therapy Market Value, 2022-2031 (US$ Million)

Figure 21 Others End-User in Global Non-Invasive Diabetes Therapy Market Value, 2022-2031 (US$ Million)

Figure 22 Global Non-Invasive Diabetes Therapy Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 23 North America Non-Invasive Diabetes Therapy Market Value, 2022-2031 (US$ Million)

Figure 24 North America Non-Invasive Diabetes Therapy Market Share, By Product, 2023 & 2031 (%)

Figure 25 North America Non-Invasive Diabetes Therapy Market Share, By Diabetes Type, 2023 & 2031 (%)

Figure 26 North America Non-Invasive Diabetes Therapy Market Share, By End-User, 2023 & 2031 (%)

Figure 27 North America Non-Invasive Diabetes Therapy Market Share, By Country, 2023 & 2031 (%)

Figure 28 South America Non-Invasive Diabetes Therapy Market Value, 2022-2031 (US$ Million)

Figure 29 South America Non-Invasive Diabetes Therapy Market Share, By Product, 2023 & 2031 (%)

Figure 30 South America Non-Invasive Diabetes Therapy Market Share, By Diabetes Type, 2023 & 2031 (%)

Figure 31 South America Non-Invasive Diabetes Therapy Market Share, By End-User, 2023 & 2031 (%)

Figure 32 South America Non-Invasive Diabetes Therapy Market Share, By Country, 2023 & 2031 (%)

Figure 33 Europe Non-Invasive Diabetes Therapy Market Value, 2022-2031 (US$ Million)

Figure 34 Europe Non-Invasive Diabetes Therapy Market Share, By Product, 2023 & 2031 (%)

Figure 35 Europe Non-Invasive Diabetes Therapy Market Share, By Diabetes Type, 2023 & 2031 (%)

Figure 36 Europe Non-Invasive Diabetes Therapy Market Share, By End-User, 2023 & 2031 (%)

Figure 37 Europe Non-Invasive Diabetes Therapy Market Share, By Country, 2023 & 2031 (%)

Figure 38 Asia-Pacific Non-Invasive Diabetes Therapy Market Value, 2022-2031 (US$ Million)

Figure 39 Asia-Pacific Non-Invasive Diabetes Therapy Market Share, By Product, 2023 & 2031 (%)

Figure 40 Asia-Pacific Non-Invasive Diabetes Therapy Market Share, By Diabetes Type, 2023 & 2031 (%)

Figure 41 Asia-Pacific Non-Invasive Diabetes Therapy Market Share, By End-User, 2023 & 2031 (%)

Figure 42 Asia-Pacific Non-Invasive Diabetes Therapy Market Share, By Country, 2023 & 2031 (%)

Figure 43 Middle East and Africa Non-Invasive Diabetes Therapy Market Value, 2022-2031 (US$ Million)

Figure 44 Middle East and Africa Non-Invasive Diabetes Therapy Market Share, By Product, 2023 & 2031 (%)

Figure 45 Middle East and Africa Non-Invasive Diabetes Therapy Market Share, By Diabetes Type, 2023 & 2031 (%)

Figure 46 Middle East and Africa Non-Invasive Diabetes Therapy Market Share, By End-User, 2023 & 2031 (%)

Figure 47 Oramed: Financials

Figure 48 Novo Nordisk A/S: Financials

Figure 49 Biocon: Financials

Figure 50 Merck KGaA: Financials

Figure 51 Pfizer Inc.: Financials

Figure 52 Teva Pharmaceutical Industries Ltd.: Financials

Figure 53 Abbott: Financials

Figure 54 AstraZeneca: Financials

Figure 55 Eli Lilly and Company: Financials

Figure 56 Novartis AG: Financials

글로벌 비침습적 당뇨병 치료 시장 – 2024년 – 2031년

Global Non-Invasive Diabetes Therapy Market - 2024 - 2031